How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: ALN-APP (drug), Placebo (drug)
How long the study runs: Study runs about 86 months (dates as stated)
About the drug or intervention: ALN-APP — drug: ALN-APP will be administered intrathecally (IT) · Placebo — drug: Placebo will be administered IT
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 60
Started: 2022-02-04
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for early-onset alzheimer disease
• Phase1 - 60 participants
• The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD)

Who can take part?

• Ages 18 Years and over
• Diagnosed with early-onset alzheimer disease

Where?

• Huntley Street - Clinical Trial Site
• Sheffield - Clinical Trial Site

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.

Early-Onset Alzheimer Disease

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

Biomarkers mentioned

eGFR

What the study is looking for

✓Has mild cognitive impairment or mild dementia due to EOAD
✓Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and Mini Mental State Examination (MMSE) \>20

Who cannot take part

✗Has Non-Alzheimer's disease dementia
✗Has alanine aminotransferase (liver enzymes) or aspartate aminotransferase (liver enzymes) \>2×upper limit of normal (ULN)
✗Has estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m\^2 at Screening
✗Has recently received an investigational agent
✗Has recent treatment with amyloid-targeting antibody

See the full criteria

Inclusion Criteria: * Has mild cognitive impairment or mild dementia due to EOAD * Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and Mini Mental State Examination (MMSE) \>20 Exclusion Criteria: * Has Non-Alzheimer's disease dementia * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2×upper limit of normal (ULN) * Has estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m\^2 at Screening * Has recently received an investigational agent * Has recent treatment with amyloid-targeting antibody Note: other protocol defined inclusion / exclusion criteria apply

Where Is This Study? (2 UK sites)

Clinical Trial Site

Huntley Street WC1E 6AG, United Kingdom

Recruiting

Clinical Trial Site

Sheffield S10 2JF, United Kingdom

Recruiting

How to Get in Touch

Alnylam Clinical Trial Information Line

Sponsor contact

CONTACT

1-877-ALNYLAM clinicaltrials@alnylam.com

Alnylam Clinical Trial Information Line

Sponsor contact

CONTACT

1-877-256-9526 clinicaltrials@alnylam.com

Data sourced from ClinicalTrials.gov · Last verified: 2026-09